Get the Stockscreener App
13.42
1.13%
0.15
After Hours:
13.65
0.23
+1.71%
Climb Bio Inc stock is traded at $13.42, with a volume of 1.26M.
It is up +1.13% in the last 24 hours and up +27.20% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
See More
Previous Close:
$13.27
Open:
$13.36
24h Volume:
1.26M
Relative Volume:
1.13
Market Cap:
$768.47M
Revenue:
-
Net Income/Loss:
$-52.79M
P/E Ratio:
-17.23
EPS:
-0.7789
Net Cash Flow:
$-53.49M
1W Performance:
+2.91%
1M Performance:
+27.20%
6M Performance:
+219.52%
1Y Performance:
+965.08%
1-Day Range:
$12.84
$13.71
1-Week Range:
$12.34
$14.41
52-Week Range:
$1.21
$14.41
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
13.42 | 759.88M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Mizuho | Outperform |
| Mar-24-26 | Initiated | B. Riley Securities | Buy |
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Mar-05-26 | Initiated | Wedbush | Outperform |
| Feb-13-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com Canada
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio Appoints Breanna O’Reilly to Board - TipRanks
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com South Africa
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Australia
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Small Cap Completeness Index - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio, Inc. Actuals & Estimates (NASDAQ:CLYM) - TradingView
NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients - Traders Union
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Climb Bio stock price target reiterated at $20 by H.C. Wainwright - Investing.com UK
CLYM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Climb Bio stock price target reiterated at $20 by H.C. Wainwright By Investing.com - Investing.com India
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLYM Q1 2026 Earnings: Narrower-than-expected loss highlights progress despite no revenueEarnings Revision Downgrade - dars.gov.et
CLYM News | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Climb Bio Inc (CLYM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Climb Bio Inc (CLYM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Climb Bio Inc (CLYM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Surprise Stocks - newsline.com
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM) - The Globe and Mail
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):